Celtic Pharmaceutical Holdings LP (“Celtic Pharma”), the international private equity firm focused on the biotechnology and pharmaceutical industries, and Munich-based IDEA AG (“IDEA”) today announce that a Celtic Pharma subsidiary, TDT, has acquired an exclusive global license to IDEA’s Transfersome® targeted delivery technology, including global rights to all IDEA’s products in clinical and pre-clinical development except for IDEA’s lead product, IDEA-033, an NSAID indicated against “deep pain”, which IDEA will continue to develop independently of TDT.
